All but one of the healthy volunteers had CXCL13 concentrations below or at the LoD, whereas about half of the patients with MS had detectable concentrations at baseline (1/32 vs 22/45, p < 0.0001). This evidence concerns the gene CXCL13 and myeloid sarcoma.